These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6393227)

  • 21. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia.
    Olsson AG; Lang PD; Vollmar J
    Atherosclerosis; 1985 May; 55(2):195-203. PubMed ID: 4004990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
    Andĕl M; Brodan V; Kucerová L; Brodanová M
    Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
    Bergemann R; Brandt A; Siegrist W
    Pharmacoeconomics; 1993 Feb; 3(2):131-9. PubMed ID: 10146961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of lipanthyl therapy on hyperlipoproteinemia type II/a, II/b and IV].
    Karádi I; Pados G; Németh-Csóka M; Romics L
    Orv Hetil; 1988 Aug; 129(33):1757-60. PubMed ID: 3174116
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of bezafibrate on disorders of lipid metabolism].
    Stryjek-Kamińska D; Ilińska-Debniak K; Bartosiewicz W; Szczepanik Z
    Pol Tyg Lek; 1983 Dec; 38(50):1567-71. PubMed ID: 6379618
    [No Abstract]   [Full Text] [Related]  

  • 27. [Increase in the fibrinolytic activity in patients with hyperlipoproteinemias type IV treated with bezafibrate].
    Obispo TM; García Fradé LJ; García Avelló A; César J; Sastre A; Navarro JL
    Rev Clin Esp; 1988 Feb; 182(3):151-4. PubMed ID: 3368592
    [No Abstract]   [Full Text] [Related]  

  • 28. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 29. Hypolipidemic effects of bezafibrate: studies in Italy.
    Postiglione A; Riccardi G; Saldalamacchia G
    Monogr Atheroscler; 1986; 14():198-202. PubMed ID: 3526125
    [No Abstract]   [Full Text] [Related]  

  • 30. [The effect of long-term hypolipemic treatment with bezafibrate on the lithogenesis of bile in persons with endogenous hypertriglyceridemia].
    Hrabák P; Zák A; Zeman M; Skorepa J; Hrubant K
    Cas Lek Cesk; 1986 May; 125(21):651-4. PubMed ID: 3708672
    [No Abstract]   [Full Text] [Related]  

  • 31. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 32. [Platelet aggregation in patients with hyperlipoproteinemia treated with bezafibrate].
    Borowska A; Bachórzewska-Gajewska H; Kaliciński A
    Pol Tyg Lek; 1986 Mar; 41(9):273-6. PubMed ID: 3714570
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 34. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of the combined administration of guar-bezafibrate on lipid, apolipoprotein and lipoprotein in patients with primary hyperlipoproteinemia type II].
    Wirth A; Schlierf G; Middelhoff G; Arntz HR; Hansen W; Vollmar J; Bräuning C
    Beitr Infusionther Klin Ernahr; 1983; 12():99-108. PubMed ID: 6316922
    [No Abstract]   [Full Text] [Related]  

  • 36. Gemfibrozil--a new lipid lowering agent.
    Nash DT
    J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 39. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.